Connect with us

News

The heart of the matter: How CordiFio is creating change

FemTech World speaks to Petronela Sandulache of CorDiFio about why heart condition diagnoses are harder for women

Published

on

Heart health attacks CorDiFio

Heart health for women can be a difficult diagnosis to make due to symptoms mirroring other conditions. FemTech World meets Petronela Sandulache founder of CorDiFio

Petronela started her career in the consulting and automotive industry all over the world before a family tragedy made her assess her goals.

She said: “When something terrible happened in my family, it made me think about life and what it is all about. The most important person in our lives had a misdiagnosis and that was it. Someone who is relatively healthy just disappears overnight. That was when I started to investigate the disparities in medical diagnosis for women.”

Petronella added: “Women present different types of symptoms that get confused with indigestion or anxiety rather than being taken seriously and having a further investigation. Once I started investigating, I found out that the number one killer of women more than all cancers combined is heart disease yet 50 per cent following an attack get misdiagnosed.

This is huge pressure on the healthcare system because misdiagnosis means wrong treatments and doctors. The ones who are paying the price are women.”

Heart health attacks CorDiFio

Heart attacks and health

When it comes to heart attacks, women present different symptoms to men. Yet when it comes to diagnosis, the male symptoms are often used as a benchmark for how it presents.

Petronela explained: “In research conducted by the Canadian stroke and heart foundation, they discovered that 30 to 50 per cent of women diagnosed with depression are actually misdiagnosed and this can mask heart disease in women. They have only recently started to investigate the problem of heart disease, stroke or Alzheimer’s disease in women and why things present differently.”

Hormones are one reason why women have been excluded from studies and it’s why certain conditions present differently in women. Women also face challenges when it comes to taking part in clinical trials such as childcare or pregnancy.

“Obviously we have hormones that are not taken into consideration when you just study male models. So I thought we need to do something about this because femtech is just about tracking your period, making babies or menopause. Women are much more than their reproductive organs. Everything we know about common diseases, treatments and diagnosis has been done on men,” Petronela said.

“We need to do something about heart disease because if you don’t know that you have it, then you can be gone in five minutes. That’s why I called the company, CorDiFio, it means, in Italian, the heart of Fio which was the name of my mother. I’m dedicating this to her and all the women out there so they don’t need to go through the same type of thing,” she added.

The research also revealed that different ethnic backgrounds may place women at higher risks for cardiovascular diseases.

Petronela said: “It’s important to note within the female population, we have ethnic backgrounds with different risk profiles. We know that African, Hispanic or southeast Asian women have a higher probability of dying from cardiovascular disease compared to caucasian women.”

Heart health awareness

CorDioFio is dedicated to raising awareness so that women can detect heart problems early before it becomes a medical emergency. Its goal is to empower both women and their doctors to come up with early detection which will help to save lives.

“The great news is that 80 per cent of heart disease and strokes are preventable if caught in time. We are determined to keep women’s hearts beating longer.”

When it comes to CorDiFio’s technology, how does it work for patients?

Petronella explained: “If you download our app or go to the website to register then we take you on a journey by asking specific questions that take about 20 minutes to answer. We will generate a personalised health report for you to download and take to your appointment with your GP. You will learn your risk factors, where you need to keep an eye out and it’s something tangible to start that conversation with doctors by highlighting things you wouldn’t have thought of.”

She added: “We have tested this with various women from all over the world to see what their doctors say about the reports. They found that they don’t have a heart problem which is great so it’s peace of mind but some found they had other issues which present a diagnostic opportunity. We want to integrate this and are working with wearables.”

Read more about femtech and CorDiFio

Diagnosis

Lung cancer drug shows breast cancer potential

Published

on

Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.

PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.

Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.

The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.

In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.

Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.

Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.

Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”

John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”

Continue Reading

Pregnancy

Higher nighttime temps linked to increased risk of autism diagnosis in children – study

Published

on

Nighttime temperatures during pregnancy may be linked to a higher chance of an autism diagnosis in children, a recent study suggests.

The research tracked nearly 295,000 mother-child pairs in Southern California from 2001 to 2014 and linked warmer overnight temperatures with higher risk in early and late pregnancy.

Children of mothers exposed to higher than typical nighttime temperatures during weeks one to 10 of pregnancy had a 15 per cent higher risk of an autism diagnosis.

Exposure during weeks 30 to 37 was linked to a 13 per cent higher risk.

 Lead author David Luglio, a post-doctoral fellow at Tulane University, said: “A key takeaway is that we identified specific windows when a mother and her developing child can be most affected by exposures to higher nighttime temperatures.

“This is critical and hopefully can help mothers prepare accordingly.”

The study is described as the first to examine how temperature may affect fetal neurodevelopment, the process by which a baby’s brain and nervous system form during pregnancy.

Extreme temperatures linked to increased risk were classified as above the 90th percentile, meaning 3.6°F hotter than average, and the 99th percentile, 5.6°F above average.

The association held even after researchers accounted for factors such as neighbourhood conditions, vegetation and fine-particle air pollution.

The study could not account for other factors such as access to air conditioning. Researchers did not find the same association with daytime temperatures, potentially because people spend more time away from home during the day.

“Heat waves are becoming more frequent, and people may only think of the dangers of daytime heat exposure,” said Mostafijur Rahman, assistant professor of environmental health sciences at Tulane University.

“These results indicate a strong association between high nighttime temperatures during pregnancy and autism risk in children and show that we need to think about exposure to heat around the clock.”

The study did not examine how higher temperatures at night might affect prenatal development, though Luglio said it is possible that warmer nights disrupt sleep for pregnant mothers.

Previous research has suggested insufficient sleep during pregnancy may be linked to a higher risk of neurocognitive delays in children.

“Extreme heat exposure during pregnancy has been linked to a range of adverse health outcomes, including prenatal neurodevelopment delays and complications with an embryo’s development of a central nervous system,” Luglio said.

“The goal of our study was to specifically explore the link between prenatal heat exposure and autism diagnoses for the first time.”

Continue Reading

Entrepreneur

Kindbody unveils next-gen fertility platform

Published

on

Kindbody has launched a fertility platform integrating AI with clinical care and patient support for employers and health plans.

The platform will enter a pilot with select Kindbody employer clients in 2026, covering over three million lives, ahead of wider availability in 2027.

Building on the company’s clinical model, the platform aims to improve outcomes and cost efficiency across family-building journeys. It connects Kindbody-owned clinics, partner clinics and an integrated clinical app.

The app offers virtual care across conception, pregnancy and reproductive health, extending through the menopause transition.

Launch features include updates in medication management, third-party reproduction, adoption, pregnancy, men’s health and global programme design.

David Stern, chief executive of Kindbody, said: “With our next-generation fertility platform, Kindbody is redefining what comprehensive, intelligent and affordable family-building care looks like for employers, health plans and patients.

“By unifying best-in-class clinical care, AI-driven intelligence and whole-person support, we are making it easier and more cost-effective for more people to build the families they envision.”

Kindbody has expanded access via its national network of IVF centres, including IVIRMA, Inception Fertility and Ivy Fertility.

A new Fertility Medication Portal is designed to streamline authorisations so medicines can be dispensed on time, giving patients visibility from prescription to coverage, pharmacy fulfilment and delivery tracking.

Through KindMan, men’s health education, digital resources and integrated clinical care are expanding, including hormone management programmes.

Services cover andropause (age-related testosterone decline), erectile dysfunction, low testosterone and other male reproductive conditions.

Specialist fertility care includes semen analysis, diagnostic testing, male hormone panels, genetic testing, surgical sperm extraction and sperm cryopreservation.

Launching in the second quarter, a pregnancy support app will act as a digital companion for expecting and new parents, with resources, interactive tools and clinical assessments to identify social drivers of health and mental health needs during pregnancy and beyond.

Kindbody’s physician-led menopause programme provides consultations with board-certified obstetricians and gynaecologists to diagnose, treat and manage menopausal symptoms, including hormone replacement therapy where appropriate, with support from nutritionists, mental health therapists and pelvic floor specialists.

AI and analytics will be embedded across the care journey. An AI care navigator will guide employees from benefit activation through intake, triage and scheduling.

Tools will track benefits and treatment plans, showing coverage and expected out-of-pocket costs at each step.

AI-supported scribing will assist clinicians with documentation, and a predictor tool will estimate a patient’s likelihood of having a baby across different treatment paths.

In 2027, Kindbody plans a savings model for eligible large employers that it says will guarantee lower total fertility spend while improving clinical efficiency and patient experience.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.